NCT01882374View on ClinicalTrials.gov

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Hematologic Malignancies
Interventions
DRUG

TXA127

Injection, 300mcg/kg/day for 28 days

Trial Locations (1)

22903

University of Virginia Cancer Center, Charlottesville

Sponsors
All Listed Sponsors
lead

Tarix Pharmaceuticals

INDUSTRY